<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5487">
  <stage>Registered</stage>
  <submitdate>11/10/2007</submitdate>
  <approvaldate>11/10/2007</approvaldate>
  <nctid>NCT00543439</nctid>
  <trial_identification>
    <studytitle>Study Evaluating Prophylaxis Treatment &amp; Characterizing Efficacy, Safety, &amp; PK Of B-Domain Deleted Recombinant FVIII</studytitle>
    <scientifictitle>An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B1831001</secondaryid>
    <secondaryid>3082B2-313</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemophilia A</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Moroctocog alfa (AF-CC)
Other interventions - Moroctocog alfa (AF-CC)

Experimental: 1 - On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.

Experimental: 2 - Routine Prophylaxis Crossover


Other interventions: Moroctocog alfa (AF-CC)
On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.

Other interventions: Moroctocog alfa (AF-CC)
Routine prophylaxis crossover:
45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The annualized bleed rate is the primary endpoint for testing the primary objective of the study (comparing prophylaxis to on-demand therapy)</outcome>
      <timepoint>End of Study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The annualized bleed rate is the endpoint for testing one of the secondary objectives (comparing high vs low frequency prophylaxis regimens).</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of moroctocog alfa (AF-CC) infusions per bleed</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response of bleed to moroctocog alfa (AF-CC) treatment (4-point scale of assessment)</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time interval between bleed onset and prior moroctocog alfa (AF-CC) prophylaxis dose</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of prophylaxis regimen escalation</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Less than Expected Therapeutic Effect</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Consumption of moroctocog alfa (AF-CC)</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compliance with assigned prophylaxis regimen</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Adverse Events</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of confirmed FVIII inhibitor development</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male subjects, aged less than 6 years, with moderately severe to severe hemophilia A.

          -  A negative FVIII inhibitor titer at screening, and a medical history negative for a
             past FVIII inhibitor.

          -  At least 20 exposure days to any FVIII replacement product.

          -  Adequate hepatic and renal function

          -  CD4 count &gt; 400 cells/uL, and if receiving antiviral therapy must be on a stable
             regimen

        Additional criteria for subjects participating in the PK assessment:

          -  Male subjects as described immediately above except they must have a FVIII Activity of
             less than or equal to 1% confirmed by the central laboratory screening test

          -  Age &lt; 6 years at time of PK assessment.

          -  The subject's size is sufficient to permit PK-related phlebotomy.

          -  The subject is able to comply with the procedures conducted during the PK assessment,
             including a mandatory 72-hour washout period preceding the PK assessment.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>15</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A history of FVIII inhibitor.

          -  Presence of a bleeding disorder in addition to hemophilia A.

          -  Treatment with any investigational drug or device within 30 days before the time of
             signing the informed consent form.

          -  Major or orthopedic surgery planned to occur during the course of the study.

          -  Regular (e.g., daily, every other day) use of antifibrinolytic agents or medications
             known to influence platelet function such as aspirin or certain nonsteroidal
             anti-inflammatory drugs (NSAIDs), or regular, concomitant therapy with
             immunomodulating drugs (e.g., intravenous immunoglobulin [IVIG], routine systemic
             corticosteroids).

          -  Known hypersensitivity to hamster protein.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>11/12/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>66</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>23/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Split</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state>Irbid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey, Nuevo Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>South Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Oman</country>
      <state>Muscat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Arequipa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Adana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bornova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kurupelit</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kayseri</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this research study is to determine the effectiveness, safety, and
      pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are
      younger than 6 years of age, with severe or moderately severe hemophilia A.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00543439</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>